Sometimes digging deeper makes the thesis stronger, not weaker.
There is a habit I have been trying to eliminate from my own investing.
A company I like reports earnings. I open the release and immediately start looking for confirmation.
Revenue up.
Good.
Adjusted EBITDA improving.
Better.
Cash balance higher.
Great.
New stores, new distribution, new customers, another acquisition, another contract.
Bullish.
The problem is not that any of those numbers are necessarily wrong.
The problem is that a financial statement can contain entirely accurate numbers and still leave you with the wrong understanding of the business if you give the wrong numbers too much weight.
That is the central lesson I took from Thornton O’Glove’s Quality of Earnings.
The book was published in 1987, so you obviously cannot take every accounting convention and transplant it directly into a 2026 Canadian IFRS environment. But its analytical framework has aged remarkably well. O’Glove spends entire chapters on shareholder communications, differential disclosure, non operating and non recurring items, changes in expenses, receivables, inventories, debt, cash flow and accounting changes.
The underlying question running through all of it is remarkably simple:
What is actually happening inside the business?
Not:
What did management headline?
Not:
What did somebody on X say?
Not:
What multiple does Yahoo Finance show?
And not even:
What was reported EPS?
The real question is:
Why is that number what it is, how repeatable is it, and what does it tell me about the economics of the company?
For Canadian microcaps, I would take that framework one step further.
We need to analyze not only the quality of earnings, but also the quality of financing, quality of dilution and quality of growth.
Because on the Venture and CSE, those things can determine the investment outcome just as much as the income statement.
And two companies I follow closely Happy Belly Food Group and Glow LifeTech illustrate why this type of analysis does not have to be a hunt for bad news.
Sometimes the deeper you dig, the more interesting the thesis becomes.
Quality of earnings does not mean “find something wrong”
This is an important distinction.
Forensic accounting can become an ideological exercise if you aren’t careful.
You can convince yourself that every non GAAP number is bullshit, every warrant is bad, every increase in receivables is suspicious and every management statement is promotional.
That’s not analysis.
That’s just cynicism wearing a spreadsheet.
The goal should be to separate three things:
Reported accounting results.
Management’s explanation of those results.
The economic reality underneath both.
Sometimes the accounting result flatters the business.
Sometimes it makes the business look worse than its recurring economics.
Sometimes an expense is very real but genuinely non recurring.
Sometimes dilution destroys shareholder value.
And sometimes dilution occurs only after shareholders have already experienced substantial value creation and then brings meaningful cash into the company.
Context matters.
Happy Belly is a very good example.
Happy Belly Food Group: the IFRS loss does not tell the whole story
If you looked only at Happy Belly’s Q2 2026 IFRS income statement, you could come away with a very strange impression of the quarter.
The company reported a $4.62 million loss from continuing operations in Q2.
That is a reported fact.
But now look at what was happening operationally.
Happy Belly generated $28.4 million of QSR system wide sales, up approximately 75% from $16.2 million a year earlier and approximately 47% sequentially. The system reached 95 operating restaurants, up roughly 53% from 62 a year earlier.
Reported Q2 revenue increased approximately 57% to $8.5 million, while royalties and franchise fees increased approximately 129% to $1.6 million.
Adjusted EBITDA increased to approximately $720,000, or an 8.5% margin, from approximately $510,000 in the comparable quarter.
Cash stood at approximately $12.0 million at June 30, compared with about $3.0 million one year earlier. Those are reported figures from Happy Belly’s Q2 2026 MD&A, page 2.
So how do we reconcile a business producing those operating numbers with a $4.6 million IFRS loss?
This is exactly where Quality of Earnings becomes useful.
Start with the $4.08 million share-based compensation charge
Happy Belly recorded approximately $4.08 million of share based compensation in Q2 and approximately $8.19 million during the first six months of 2026. Those expenses are included in the company’s IFRS results. Happy Belly Q2 2026 financial statements, page 5.
The approximately $8.19 million recognized in H1 2026 does not principally represent the older Phase I securities being written off as they were exercised. Those Phase I exercises issued shares and brought cash into treasury. The large share based compensation charge recorded in the income statement instead relates to the newer Phase II performance awards, which generally carry a $2.00 exercise price and vesting conditions tied to business performance and share-price milestones extending from $3 to $10.
Under IFRS 2, Happy Belly does not wait until the share price milestones are achieved, or until the awards vest or are exercised, before recording the accounting expense. The estimated grant date fair value is recognized over an estimated five year service period using graded vesting, producing a front loaded expense profile. Happy Belly projects approximately $15.04 million of Phase II SBC in 2026 and approximately $35.99 million cumulatively through 2030. The expense is a genuine accounting cost and the potential dilution is real, but it is not a recurring cash operating cost of the restaurant business.
That expense should not simply be ignored.
Equity belongs to shareholders. Issuing equity based compensation has an economic cost.
But neither should we pretend Happy Belly’s restaurants wrote a $4.08 million cheque during Q2 to pay it.
The IFRS loss and Adjusted EBITDA are answering two different questions.
The IFRS statement asks:
What accounting costs were attributable to shareholders during the period?
Adjusted EBITDA is attempting to answer:
What did the recurring operating business produce before certain non-cash and non-recurring items?
A serious investor should understand both.
Choosing whichever number supports your existing opinion is precisely what we are trying to avoid.
Then there is the $674,008 Employer Health Tax
This is the part that deserves much more attention than I initially gave it.
Included within Happy Belly’s salaries and wages for the period was $674,008 of Employer Health Tax, or EHT, generated by gains realized when stock options and warrants were exercised.
The company explicitly identifies the EHT as non recurring, stating that it arose specifically from those equity exercises and is not reflective of normal ongoing operating activity. Happy Belly Q2 2026 financial statements, Note 18, page 23.
This isn’t imaginary.
It’s a real expense.
But it is also analytically different from paying restaurant employees, rent, food costs or recurring head office salaries.
And the event that produced that tax is where the story gets considerably more interesting.
Happy Belly’s Phase 1 warrants were built around performance
Back in June 2021, when the company was still Plant&Co — it entered into a strategic advisory arrangement that included 27 million advisory warrants exercisable at $0.20.
This was not simply 27 million warrants vesting because management managed to remain employed long enough.
Of those 27 million, 5.2 million vested upon closing of the original private placement.
The remaining 21.8 million were tied to progressively higher market-price hurdles:
$0.50.
$0.75.
$1.00.
$1.50.
$2.00.
The closing share price on the CSE had to reach those respective levels before the corresponding tranches vested.
That distinction is enormously important.
It means most of those original warrants were not earned simply because the calendar moved forward.
Shareholders had to experience substantial share price appreciation before the majority of the awards could vest.
That doesn’t make the eventual dilution disappear.
But it changes the economic bargain.
Dilution is not one single thing
Microcap investors tend to discuss dilution as though every additional share has identical economics.
It doesn’t.
Consider two hypothetical companies.
Company A is running out of cash. Its share price has collapsed. Management announces a deeply discounted placement with half warrants attached because it has no other way to fund operations.
Company B creates performance incentives when its shares are trading in the teens. Those incentives vest only after the company’s share price crosses successively higher thresholds, culminating at $2.00. The holders then have to put cash into the company to exercise those securities.
Both companies issued more shares.
Those are not economically equivalent events.
Happy Belly’s Phase 1 structure looks much closer to Company B.
In its June 19, 2026 announcement, Happy Belly reported that 100% of the performance warrants and options expiring June 18 had been exercised, completing what management called Phase 1 of its strategic growth and self-funding plan.
The company said approximately 31 million performance options and warrants had been exercised since January 2026, putting approximately $8.35 million directly into treasury.
And the subsequently filed financial statements give us another useful reconciliation.
Through June 30, Happy Belly reported $3.392 million of proceeds from option exercises and $5.963 million from warrant exercises, or approximately $9.35 million combined from all option and warrant exercises during the first half. Happy Belly Q2 2026 financial statements, page 7.
The numbers are slightly different because the June 19 Phase 1 announcement refers specifically to the Phase 1 securities it was discussing, while the June 30 financial statements capture total exercise proceeds during the full six month reporting period.
That is exactly the sort of reconciliation investors should be doing.
Is that shareholder friendly dilution?
I think the defensible answer is:
It is unusually shareholder aligned dilution by microcap standards.
But shareholder aligned.
Why?
Because the sequence matters.
The share price first had to appreciate enough for the performance conditions to be achieved.
Then the awards vested.
Then the holders still had to pay their exercise prices.
Then that exercise capital went into Happy Belly’s treasury.
So instead of:
financial distress → cheap financing → shareholder dilution
the Phase 1 mechanism was largely:
shareholder value creation → performance vesting → exercise → additional treasury capital.
That is a materially different capital formation model.
And it matters when interpreting the dilution, the exercise proceeds and the separate accounting charges associated principally with the Phase II awards.
Phase 2 takes the same idea much further
Happy Belly has since established a Phase 2 compensation structure with new performance options and warrants carrying a $2.00 exercise price and vesting conditions tied to both business performance and share price milestones extending from $3- $10 per share.
The company says those awards also require continued business performance, including growth in royalty/franchise income and sustained positive Adjusted EBITDA. At full vesting and exercise, management says executives and directors would have to invest more than $60 million back into Happy Belly.
That $60 million is a management projection of what full exercise could produce, not guaranteed future capital.
The $10 share price objective is obviously not guaranteed either.
But the incentive architecture exists today.
And from an alignment perspective, I would much rather see management build compensation around:
“We get substantially rewarded if shareholders get substantially rewarded first”
than:
“Here are millions of cheap shares regardless of what happens.”
That distinction belongs in any serious analysis of HBFG’s share-based compensation.
So what is actually happening underneath Happy Belly’s accounting loss?
Once the accounting noise is identified, the operating question becomes much clearer.
Happy Belly’s Q2 product sales were approximately $6.42 million, while franchise revenue reached approximately $1.60 million. The company reported 95 operating QSR locations, compared with 62 in Q2 2025. Its quarterly operating metrics show royalty and fee revenue rising alongside the expanding restaurant base. Happy Belly Q2 2026 MD&A, page 8.
That franchise revenue matters.
A company that has to own every incremental restaurant itself requires one kind of capital structure.
A company that can increasingly earn recurring royalty revenue from stores funded and operated by franchisees potentially has a very different scaling profile.
Management describes its strategy as franchise led and asset light.
That is a management assertion.
But the growth in royalty and franchise fee revenue provides actual reported evidence we can use to test whether the strategy is beginning to appear in the numbers.
My analytical inference is therefore not:
“HBFG’s accounting losses don’t matter.”
They do.
It is:
HBFG’s reported loss contains substantial equity compensation and one time EHT costs that should be separated from the recurring economics of its rapidly expanding QSR and franchise platform. The key proof point now is whether royalty growth and system scale begin producing increasingly visible operating leverage.
That’s a far more useful conclusion.
Glow LifeTech: a different version of improving earnings quality
Glow LifeTech provides another example, but the story is completely different.
Glow is much smaller.
It isn’t building a national restaurant platform.
The question here is simpler:
As revenue grows, is the business actually moving toward economic breakeven?
The latest numbers say it is moving in that direction.
In Q2 2026, Glow generated $522,968 of revenue, up approximately 20% from $436,325 a year earlier.
Gross profit increased to $328,309 from $293,141.
Now look at expenses.
Total expenses fell to $481,490 from $675,869.
The operating loss therefore narrowed dramatically to $153,181 from $382,728, while the quarterly net loss improved to $139,217 from $371,566.
Through the first six months, revenue increased to approximately $1.17 million from $915,000, while the six-month net loss narrowed to just $198,081 from $519,174. Glow Q2 2026 interim financial statements, page 4.
That is what I want to see in an early-stage microcap.
Not merely:
Revenue up.
But:
Revenue up.
Gross profit dollars up.
Expenses down.
Operating loss down.
Net loss down.
That is the beginning of operating leverage.
Glow’s cash flow provides another confirmation point
Glow’s Q2 MD&A reports $3,852 of positive cash flow from operating activities during Q2 2026, an improvement of approximately $35,000 from the comparable quarter.
That’s obviously not enough money to celebrate by itself.
The number is tiny.
But crossing from negative to slightly positive quarterly operating cash flow while simultaneously growing revenue is directionally important.
Glow also reported that its Q2 EBITDA loss narrowed approximately 46% to $89,145 from $164,900.
Working capital improved to approximately $1.81 million, while its current ratio increased to approximately 2.62x. Glow Q2 2026 MD&A, pages 5–6.
Again, none of those numbers individually proves sustainable profitability.
Together, however, they form a pattern.
And the pattern is what matters.
Glow also quietly cleaned up something I care about enormously: the warrant overhang
There is another quality-of-capital point here.
At the beginning of 2026, Glow still had a substantial warrant structure outstanding.
By June 30?
Zero warrants remained outstanding.
During the first six months, approximately 10.9 million warrants were exercised, bringing approximately $544,913 into the company, while approximately 39 million additional warrants expired. Glow Q2 2026 financial statements, pages 5 and 25.
Glow’s MD&A goes further and says that, across the prior three quarters, more than 70 million warrants had been eliminated, leaving the company warrant-free at quarter-end.
That matters to me.
A warrant overhang creates potential future dilution and can affect how a microcap trades.
Once those warrants are exercised or expire, that uncertainty disappears.
Glow’s share count did increase as warrants were exercised again, dilution is dilution but the company also received exercise capital, strengthened its cash position and eliminated the future warrant overhang.
At June 30, cash stood at approximately $1.60 million, compared with $1.37 million at December 31, while total current liabilities had declined to approximately $1.11 million from $1.20 million. Shareholders’ equity increased to approximately $3.07 million from $2.71 million. Glow Q2 2026 financial statements, page 3.
That’s a healthier capital structure than the one Glow entered the year with.
But this is where discipline still matters
Being bullish on a company does not mean pretending every number is perfect.
Glow’s Q2 gross margin was approximately 63% versus 67% a year earlier.
Accounts receivable increased from approximately $445,000 at year end to $543,000, and inventory increased from approximately $430,000 to $562,000. Glow Q2 2026 financial statements, pages 3–4.
Those aren’t reasons for me to throw away the thesis.
They’re things to monitor.
O’Glove spends substantial time on receivables and inventory for precisely this reason. If those assets begin growing much faster than sales for an extended period, the balance sheet can be telling you something the headline revenue figure isn’t.
In Glow’s case, my current question is not:
“Are receivables and inventory increasing?”
They are.
My question is:
Are they increasing because the company is expanding distribution and preparing for higher sales, and do those balances subsequently convert into revenue and cash?
That is something future quarters can answer.
This is the part of Quality of Earnings I find most useful
The lesson isn’t that you should distrust everything.
It is that numbers need context.
Consider how differently these statements read once you ask one additional question.
“Happy Belly lost $4.6 million.”
Okay.
Why?
A large portion came from share-based compensation, alongside a $674,000 non recurring EHT charge associated with equity exercises.
“HBFG issued millions of shares.”
Okay.
Under what conditions?
Most of the original Phase 1 advisory warrants required the share price to first rise through performance hurdles extending to $2.00, after which exercising the securities put cash into treasury.
“Glow’s shares outstanding increased.”
Okay.
What happened to the capital structure?
More than 10 million warrants were exercised for cash, tens of millions more expired, and Glow ended Q2 with no warrants outstanding.
“Glow’s revenue increased 20%.”
Okay.
Did the economics improve?
Expenses declined, losses narrowed materially and quarterly operating cash flow crossed slightly positive.
That is what quality-of-earnings analysis is supposed to do.
It forces you to finish the sentence.
Canadian microcaps need one extra concept: Quality of Financing
If I were rewriting O’Glove’s book specifically for the TSX Venture and CSE, I would add an entire chapter called Quality of Financing.
Because early stage companies frequently need external capital.
That isn’t inherently bad.
The relevant question is:
What did the shareholder receive for the dilution?
If a company issues 10% more shares and uses the capital to build an asset that doubles sustainable free cash flow, the dilution may have been highly accretive economically.
If it issues 30% more shares just to fund recurring overhead for another year, that’s something else.
Likewise, warrants need context.
What is the strike?
What had to happen before they vested?
Who received them?
Was the company already creating value?
How much cash will exercise produce?
What does the fully diluted share count look like afterward?
And is the company’s per share economic value improving faster than the share count?
That’s the analysis.
Five things you can put into practice immediately
Read the statements before the news release. Start with the income statement, balance sheet and cash-flow statement. Form your own view first. Then read the MD&A and management’s release. The difference between what you noticed and what management emphasized is often where the most useful questions live.
Reconcile reported earnings to recurring economics. Identify share-based compensation, fair-value changes, disposition gains, impairments, one-time taxes, restructuring expenses and other unusual items. Don’t automatically remove them. Ask whether each item is cash or non-cash, recurring or non-recurring, and whether it represents a genuine economic cost to shareholders.
Treat dilution as a transaction, not just a percentage. Track basic shares, options, warrants, RSUs, convertibles and acquisition shares. Then ask what triggered the issuance, what exercise price was paid, how much cash entered treasury and what value was created before or after the dilution. HBFG’s performance warrants are a perfect example of why the structure matters.
Track operating leverage, not just revenue growth. Put revenue, gross profit, operating expenses and operating cash flow beside each other every quarter. Glow’s latest numbers are a good example: higher revenue and gross-profit dollars alongside lower expenses and shrinking losses tells you much more than “revenue up 20%.”
Ask one question after every quarter: “Did the business become economically better per share?” Not whether the stock rose. Not whether management beat guidance. Did recurring revenue improve? Did margins strengthen? Did cash generation improve? Did liquidity strengthen? Did the capital structure become cleaner? And after accounting for dilution, does each share plausibly represent more underlying economic value than it did before?
The bottom line
I don’t think the lesson from Quality of Earnings is that investors should become suspicious of every company they own.
The better lesson is that financial statements are a language, and the headline number is rarely the entire sentence.
A large IFRS loss can exist alongside strong underlying business growth. Revenue may be accelerating, recurring or higher quality revenue may be expanding, and compensation structures may be designed so that management benefits only after shareholders first see meaningful value creation. In some cases, the exercise of those incentives can also return cash to the company.
Likewise, a very small business can still show meaningful improvement even before it reaches profitability. Revenue growth accompanied by lower expenses, narrowing losses, improving liquidity, positive operating cash flow and the removal of financing overhangs can all indicate that the underlying economics are moving in the right direction.
None of this guarantees future success.
That is not what financial analysis can tell us.
What it can tell us is whether the evidence is moving in the direction required for the investment thesis to work.
And that is the habit that matters most in Canadian microcaps:
Don’t just ask whether the number is good or bad.
Ask:
Why did it happen?
Can it repeat?
What did it cost shareholders?
What did shareholders receive in return?
And ultimately:
Is the business underneath the number getting better?
That, to me, is the real meaning of quality of earnings.